e.g. mhealth
Search Results (1 to 6 of 6 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 3 JMIR Formative Research
- 1 JMIR Human Factors
- 1 JMIR Research Protocols
- 1 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Disruption in access for patients who use buprenorphine for OUD and patients who use chronic opioid analgesic therapy may have contributed to these issues.
Patients receiving opioids for chronic pain or buprenorphine for OUD may be more likely to experience disruptions in care since buprenorphine and chronic opioid analgesic therapy are controlled substances with restrictions on prescribing [22-26].
JMIR Form Res 2025;9:e66596
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Patient Engagement in a Multimodal Digital Phenotyping Study of Opioid Use Disorder
The opioid crisis continues unabated in the United States, with 2.7 million individuals diagnosed with past-year opioid use disorder (OUD) in 2020 [1] and over 100,000 fatal overdoses from opioids in the 12 months ending in May 2022 [2]. Buprenorphine is an effective medication for treating OUD, reducing opioid use, and lowering mortality risk; yet, many do not remain in treatment, and the risk of relapse is high [3-6].
J Med Internet Res 2023;25:e45556
Download Citation: END BibTex RIS
Epidemiological occupational health studies indicated that high physical and stressful job demands were strongly associated with OUD [18,20-23]. Therefore, combining on-the-job risk factors for injury coupled with provider prescription recommendations for opioid use could elevate the risk of developing OUD within these occupational groups [1].
JMIR Form Res 2023;7:e45434
Download Citation: END BibTex RIS
Due to the many historical accessibility barriers associated with obtaining a DEA-X waiver, only about 5% of physicians in the United States have acquired this prescriptive authority, which, in turn, limits the ability to care for patients with opioid use disorder (OUD) [2]. Get Waivered (GW) was founded to address this caveat by encouraging and facilitating more clinicians in obtaining their DEA-X waiver.
JMIR Hum Factors 2023;10:e40244
Download Citation: END BibTex RIS
Unprecedented rates of opioid misuse and mortality have led to the current opioid epidemic in the United States [1], with approximately 2.5 million people in the United States meeting the criteria for opioid use disorder (OUD) in 2020 [2]. OUD is a chronic condition with numerous physical, psychological, and personal consequences, including a high risk of death, which has risen in recent years due to the increasing prevalence of potent synthetic opioids (predominantly fentanyl) [3].
JMIR Res Protoc 2023;12:e43122
Download Citation: END BibTex RIS